Embecta Corp. (NASDAQ:EMBC) Company Profile
Embecta Corp. (NASDAQ:EMBC) was founded in 1924, with its headquarters in Parsippany, New Jersey. After being spun off from Becton, Dickinson and Company, it has become one of the largest pure diabetes management companies globally, focusing on diabetes care solutions.
I. Company Introduction
Embecta Corp. was founded in 1924, with its headquarters located in Parsippany, New Jersey, and has 2,200 full-time employees. It was spun off and became independent from Becton, Dickinson and Company on April 1, 2022, and holds the previous diabetes care business of Becton, Dickinson and Company. As a global medical technology company, it focuses on developing, manufacturing, and selling diabetes management products.
Official Website: https://www.embecta.com/en-us
II. Main Business Segments
Focusing on the field of diabetes care solutions, the core business is the production of insulin delivery devices, specifically including:
-
Pen Needle Business: Provides various types of needle products for insulin pens, which are key components for insulin injection for diabetes patients.
-
Syringe Business: Produces syringes of different specifications and types to meet the diverse insulin injection needs of diabetes patients.
-
Safety Device Business: Develops and sells safety devices aimed at improving the safety and convenience of diabetes treatment, enhancing the patient's usage experience and treatment safety.
III. Technological and Business Advantages
-
Historical and Experiential Advantages: With a history of nearly 100 years, since BD launched the world's first professional insulin syringe in 1924, it has accumulated rich experience in the research, development, and production of diabetes care products, and has a profound technological foundation.
-
Focus and Professional Advantages: Focusing on the field of diabetes care, it is highly professional in insulin delivery devices, and can concentrate resources on technological innovation and product optimization to meet the ever-changing needs of diabetes patients.
-
Market Position and Scale Advantages: As one of the largest pure diabetes care companies globally and a leading producer of diabetes injection devices worldwide, it has high visibility and influence in the market. Its business spreads across more than 100 countries, and it has a large customer base. The scale effect helps with cost control and market expansion.
IV. Development History
| Time | Key Events |
|---|---|
| 1924 | BD launched the world's first professional insulin syringe, laying the foundation for the development of Embecta |
| April 1, 2022 | Spun off and became independent from Becton, Dickinson and Company (BD) to become Embecta Corp., holding BD's previous diabetes care business |
| July 22, 2024 | Hired consultants to evaluate a potential sale. Since the spin-off in April 2022, the stock price has plummeted by about 70%, possibly affected by GLP-1 drugs |
Disclaimer: The views in this article are from the original Creator and do not represent the views or position of Hawk Insight. The content of the article is for reference, communication and learning only, and does not constitute investment advice. If it involves copyright issues, please contact us for deletion.
